|
AV Junction Ablation or Optimal Medical Treatment in PatiEnts With Cardiac Resynchronization Therapy and Permanent Atrial Fibrillation
RECRUITINGN/ASponsored by University Hospital Ostrava
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital Ostrava
Started2023-04-01
Est. completion2028-12-31
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05776797
Summary
A study comparing atrioventricular junction ablation (AVJA) versus continued optimum medical rate control in patients with cardiac resynchronization therapy (CRT) and atrial fibrillation (AF) with suboptimal heart rate control on optimum medication.
Eligibility
Age: 18 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria: * Treatment with CRT using either a biventricular pacemaker/defibrillator or conduction system pacemaker (\>6 months) * Diagnosis of AF and classified as: permanent AF or recurrent persistent AF, requiring emergency visits and/or hospitalizations (at least one in recent year) * Optimized HF medical treatment and rate control medication * BiVP% + ventricular premature complex (VPC%) \<99% and \>85% during the minimum period of 1 month while already on optimum medical therapy (applicable only for patients with permanent AF) * Age \>18 and \<85 years * Signed informed consent Exclusion Criteria: * myocardial infarction (MI) or coronary artery bypass graft (CABG) \<3 months * Technical failure of the CRT system * Intentional preference for spontaneous AV conduction * Expected survival \<1 year * Other significant comorbidities and/or conditions that interfere with the proper conduction of the trial * Dementia as assessed by mini-mental test (\<23 points)
Conditions3
Heart DiseasePersistent Atrial FibrillationRecurrent Atrial Fibrillation
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital Ostrava
Started2023-04-01
Est. completion2028-12-31
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05776797